Mazdutide

Mazdutide is a GLP-1/glucagon dual agonist developed mainly for the Chinese market by Innovent Biologics, and it has only recently appeared in Western research catalogues. This page covers what it is, how it differs from the two older dual-agonist names most researchers already know, what the clinical-stage evidence actually shows so far, and how we supply the 10mg vial.

Also known as: GLP-1/glucagon dual agonist

Research context

• Dual GLP-1 and glucagon receptor activity.
• Later to the Western research market than tirzepatide.
• Single 10mg presentation.

What mazdutide actually is

Mazdutide (also referred to by its development code IB362) is a single-molecule peptide that activates two receptors at once: GLP-1, the incretin receptor that slows gastric emptying and reduces appetite, and glucagon, which raises energy expenditure in the liver. That second arm is the whole point of the design. A pure GLP-1 agonist such as semaglutide suppresses appetite but tends to reduce lean mass alongside fat; adding glucagon activity is an attempt to spend more energy so that a larger share of the weight comes from fat.

It is a 30-amino-acid analogue, produced by solid-phase synthesis, and supplied as a lyophilised white powder that is reconstituted in bacteriostatic or sterile water for laboratory use. Molecular formula C₁₆₃H₂₅₄N₄₄O₅₀S, MW approximately 3727.2 Da. In research catalogues it is most often seen in a single presentation, and only recently has the wider Western vendor market listed it at all.

How it differs from semaglutide and tirzepatide

The three names are usually confused because all three are sold for weight-loss-adjacent research. They are not the same molecule and not the same mechanism. The table below compares the pharmacology as published, not the marketing claims.

Two practical differences matter to a researcher. First, tirzepatide pairs GLP-1 with GIP, whereas mazdutide pairs GLP-1 with glucagon, so they are not interchangeable analogues of each other. Second, mazdutide has the shortest Western supply history of the four, which is why batch documentation and identity testing are worth more attention than price when you are sourcing it.

What the clinical evidence shows so far

Most of the human data on mazdutide comes from trials run in China by the originator, published across 2023 to 2026. Taken at face value, the pattern is a placebo-controlled weight reduction of roughly the same order as the established GLP-1 medicines, with gastrointestinal side effects (nausea, vomiting, diarrhoea, constipation) that follow the same profile as every other incretin-based compound. There is also Phase 2 activity being explored in non-alcoholic fatty liver disease, which is the logical place for a glucagon-containing molecule because glucagon activity is hepato-directed.

Three honest limits on that evidence, because they matter more than a headline percentage:

• Population. The pivotal trials are in Chinese populations. Body-composition response and tolerance can differ between populations, and Western data is thin.
• Comparator. Most trials are against placebo, not head-to-head against semaglutide or tirzepatide. Cross-trial percentage comparisons are not equivalence.
• Approval status. Approved in China does not mean approved in the UK, EU or US. As of 2026 there is no MHRA or EMA authorisation, so there is no approved human indication here and no legitimate dosing guidance.

Why researchers order it

Three reasons come up repeatedly. It is the cheapest way to study glucagon-arm incretin pharmacology in a single molecule without buying a triple agonist. It is a useful comparator compound when modelling energy expenditure rather than appetite alone. And it is genuinely scarce in Western catalogues, so a vial with a matching batch certificate is more useful to a lab than a vial with a lower price and no paperwork.

How we supply it

Single 10mg vial, £35.70 by card or £32.13 by bank transfer (10% off, order confirms on clearance). UK dispatch, batch documentation available on request, and cold-chain packaging in summer months. Nothing on this page is a dosing recommendation and mazdutide is not a medicine; see the research-use notice at the foot of the page.

Frequently asked questions